AIMS/HYPOTHESIS: Increased plasma concentrations of circulating adhesion molecules in patients with Type II (non-insulin-dependent) diabetes mellitus could be associated with the increased cardiovascular risk in these patients. However, it is controversial whether increased adhesion molecule plasma concentrations are primarily related to hyperglycaemia or to hyperinsulinaemia. METHODS: We evaluated the plasma concentrations of soluble E-selectin, intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) at baseline and during euglycaemic hyperinsulinaemic clamp in three different groups without additional cardiovascular risk factors: group A (control group), 28 healthy volunteers with normal glucose tolerance; group B, 24 subjects with fasting hyperinsulinaemia, normal fasting glucose but impaired glucose tolerance; group C, 32 patients with Type II diabetes, fasting hyperinsulinaemia and chronic hyperglycaemia. RESULTS: Plasma soluble E-selectin, ICAM-1, and VCAM-1 concentrations were higher ( p < 0.05) in patients with Type II diabetes (group C) compared with the other groups. The adhesion molecule concentrations correlate with the fasting plasma glucose ( r = 0.59, p < 0.001), the 2-h OGTT plasma glucose ( r = 0.70, p < 0.01), and the HbA(1 c) value ( r = 0.61, p < 0.05). The E-selectin but not the ICAM-1 and VCAM-1 plasma concentrations correlated with the fasting insulin concentrations ( r = 0.62, p < 0.05) or the whole body glucose uptake ( r = 0.59, p < 0.05) in the clamp. The hyperinsulinaemia during the euglycaemic hyperinsulinaemic clamp had no significant effect on the plasma concentrations of E-selectin, ICAM-1, and VCAM-1 in all three groups. CONCLUSION/ INTERPRETATION: Our results suggest that increased E-selectin concentrations are related to hyperglycaemia, hyperinsulinaemia and insulin resistance, whereas increased ICAM-1 and VCAM-1 plasma concentrations in patients with Type II diabetes are rather related to hyperglycaemia than to hyperinsulinaemia or insulin resistance.
AIMS/HYPOTHESIS: Increased plasma concentrations of circulating adhesion molecules in patients with Type II (non-insulin-dependent) diabetes mellitus could be associated with the increased cardiovascular risk in these patients. However, it is controversial whether increased adhesion molecule plasma concentrations are primarily related to hyperglycaemia or to hyperinsulinaemia. METHODS: We evaluated the plasma concentrations of soluble E-selectin, intracellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) at baseline and during euglycaemic hyperinsulinaemic clamp in three different groups without additional cardiovascular risk factors: group A (control group), 28 healthy volunteers with normal glucose tolerance; group B, 24 subjects with fasting hyperinsulinaemia, normal fasting glucose but impaired glucose tolerance; group C, 32 patients with Type II diabetes, fasting hyperinsulinaemia and chronic hyperglycaemia. RESULTS: Plasma soluble E-selectin, ICAM-1, and VCAM-1 concentrations were higher ( p < 0.05) in patients with Type II diabetes (group C) compared with the other groups. The adhesion molecule concentrations correlate with the fasting plasma glucose ( r = 0.59, p < 0.001), the 2-h OGTT plasma glucose ( r = 0.70, p < 0.01), and the HbA(1 c) value ( r = 0.61, p < 0.05). The E-selectin but not the ICAM-1 and VCAM-1 plasma concentrations correlated with the fasting insulin concentrations ( r = 0.62, p < 0.05) or the whole body glucose uptake ( r = 0.59, p < 0.05) in the clamp. The hyperinsulinaemia during the euglycaemic hyperinsulinaemic clamp had no significant effect on the plasma concentrations of E-selectin, ICAM-1, and VCAM-1 in all three groups. CONCLUSION/ INTERPRETATION: Our results suggest that increased E-selectin concentrations are related to hyperglycaemia, hyperinsulinaemia and insulin resistance, whereas increased ICAM-1 and VCAM-1 plasma concentrations in patients with Type II diabetes are rather related to hyperglycaemia than to hyperinsulinaemia or insulin resistance.
Authors: Julia Langhardt; Gesine Flehmig; Nora Klöting; Stefanie Lehmann; Thomas Ebert; Matthias Kern; Michael R Schön; Daniel Gärtner; Tobias Lohmann; Miriam Dressler; Mathias Fasshauer; Peter Kovacs; Michael Stumvoll; Arne Dietrich; Matthias Blüher Journal: Obes Facts Date: 2018-12-11 Impact factor: 3.942
Authors: Jang Hyun Choi; Alexander S Banks; Jennifer L Estall; Shingo Kajimura; Pontus Boström; Dina Laznik; Jorge L Ruas; Michael J Chalmers; Theodore M Kamenecka; Matthias Blüher; Patrick R Griffin; Bruce M Spiegelman Journal: Nature Date: 2010-07-22 Impact factor: 49.962
Authors: A Weingarten; L Turchetti; K Krohn; I Klöting; M Kern; P Kovacs; M Stumvoll; M Blüher; N Klöting Journal: Int J Obes (Lond) Date: 2016-07-27 Impact factor: 5.095
Authors: J Berndt; P Kovacs; K Ruschke; N Klöting; M Fasshauer; M R Schön; A Körner; M Stumvoll; M Blüher Journal: Diabetologia Date: 2007-05-11 Impact factor: 10.122
Authors: D Schleinitz; N Klöting; C M Lindgren; J Breitfeld; A Dietrich; M R Schön; T Lohmann; M Dreßler; M Stumvoll; M I McCarthy; M Blüher; P Kovacs Journal: Int J Obes (Lond) Date: 2013-04-19 Impact factor: 5.095
Authors: Yvonne Böttcher; Hanne Unbehauen; Nora Klöting; Karen Ruschke; Antje Körner; Dorit Schleinitz; Anke Tönjes; Beate Enigk; Sara Wolf; Kerstin Dietrich; Moritz Koriath; Gerhard Harry Scholz; Yu-Hua Tseng; Arne Dietrich; Michael R Schön; Wieland Kiess; Michael Stumvoll; Matthias Blüher; Peter Kovacs Journal: Diabetes Date: 2009-06-05 Impact factor: 9.461
Authors: Nora Klöting; Susan Berthold; Peter Kovacs; Michael R Schön; Mathias Fasshauer; Karen Ruschke; Michael Stumvoll; Matthias Blüher Journal: PLoS One Date: 2009-03-04 Impact factor: 3.240